![Scott Robertson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Robertson
Directeur/Membre du Conseil chez
BICARA THERAPEUTICS INC.
Fortune : - $ au 31/08/2026
Profil
Scott Robertson is currently the Independent Director at Bicara Therapeutics, Inc. since 2023, Venture Partner at Finistere Ventures LLC since 2016, and Chief Financial & Business Officer at Star Therapeutics, Inc. starting in 2024.
Former roles include Director-Business Development at EIDP, Inc., Independent Non-Executive Director at Hexima Ltd. from 2018 to 2023, Director-Business Development at DuPont Pioneer, Associate at MPM BioEquities Adviser LLC, Associate at MPM BioImpact LLC, and Chief Financial & Business Officer at DICE Molecules SV, Inc. from 2021 to 2023.
Education includes undergraduate studies at the University of Southern California and an MBA from Haas School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Postes actifs de Scott Robertson
| Sociétés | Poste | Début |
|---|---|---|
| BICARA THERAPEUTICS INC. | Directeur/Membre du Conseil | 21/09/2023 |
Finistere Ventures LLC
 Finistere Ventures LLC Investment ManagersFinance Finistere Ventures invests in companies located in the United States. The firm focuses on companies operating in broad range of sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 01/01/2016 |
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies for hematology and immunology problems | Directeur Financier/CFO | 01/01/2024 |
Anciens postes connus de Scott Robertson
| Sociétés | Poste | Fin |
|---|---|---|
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance Functions as an alternative investment manager | Directeur Financier/CFO | 01/12/2023 |
| HEXIMA LIMITED | Directeur/Membre du Conseil | 05/09/2023 |
DuPont Pioneer
 DuPont Pioneer Wholesale DistributorsDistribution Services Develops, markets and sells hybrid seeds | Corporate Officer/Principal | - |
| E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Analyste en capital-investissement | - |
Formation de Scott Robertson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
66
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries Manufactures and sells seed & crop protection products | Process Industries |
DuPont Pioneer
DuPont Pioneer Wholesale DistributorsDistribution Services Develops, markets and sells hybrid seeds | Distribution Services |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Finance |
Hexima Ltd.
 Hexima Ltd. BiotechnologyHealth Technology Engages in research and development of plant-derived proteins for treatment of fungal nail infections and provides commercial property services | Health Technology |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Finistere Ventures LLC
Finistere Ventures LLC Investment ManagersFinance Finistere Ventures invests in companies located in the United States. The firm focuses on companies operating in broad range of sectors. It provides financing for early stage capital requirements. | Finance |
Haas School of Business
 Haas School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance Functions as an alternative investment manager | Finance |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Star Therapeutics, Inc.
Star Therapeutics, Inc. BiotechnologyHealth Technology Develops antibody therapies for hematology and immunology problems | Health Technology |
